{"id":742084,"date":"2011-10-03T10:54:00","date_gmt":"2011-10-03T10:54:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\/"},"modified":"2026-08-10T13:01:16","modified_gmt":"2026-08-10T17:01:16","slug":"merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\/","title":{"rendered":"Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX\u00ae (alendronate sodium)"},"content":{"rendered":"<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,        today said a federal court jury in New York found in its favor in the <i>Secrest        v. Merck <\/i>case, rejecting the claim of a Florida woman who blamed her        dental and jaw-related problems on her FOSAMAX use.     <\/p>\n<p>       \u201cWe believe the company acted properly,\u201d said Chilton Varner of King &amp;        Spalding LLP, outside counsel for Merck. \u201cUnfortunately, the plaintiff        had medical problems that cause people to develop the jaw and dental        problems that the plaintiff has, regardless of whether they were taking        FOSAMAX. She has a long history of invasive dental procedures and        suffers from medical conditions that inhibit the body\u2019s ability to heal.\u201d     <\/p>\n<p>       Today\u2019s verdict marks the fourth time a jury has found in Merck\u2019s favor        on a plaintiff\u2019s product liability claim in the litigation regarding        FOSAMAX. The plaintiff in this case alleged she used FOSAMAX and        suffered various jaw problems and complications following multiple tooth        extractions and failed dental implants.     <\/p>\n<p>       At trial, Merck presented evidence that it acted responsibly in        researching and developing FOSAMAX and in monitoring the medicine since        it has been on the market, and that FOSAMAX is a safe and effective        medication as described in the product labeling that was properly        designed and did not cause the plaintiff\u2019s dental and jaw problems. The        company\u2019s clinical trials, conducted both before and following approval,        have involved more than 28,000 patients, including more than 17,000        treated with FOSAMAX.     <\/p>\n<p>       \u201cMerck is pleased with the jury\u2019s verdict,\u201d said Bruce N. Kuhlik,        executive vice president and general counsel of Merck. \u201cWe have now won        four of the first five cases that have been tried to verdict. We        continue to believe that FOSAMAX is a safe and effective medication and        the company provided appropriate and timely information about FOSAMAX to        consumers and to the medical, scientific and regulatory communities.\u201d     <\/p>\n<p>       U. S. District Judge John F. Keenan presided over the trial. Merck is        represented by Chilton Varner of King &amp; Spalding LLP in Atlanta, Andrew        Goldman of Goldman Ismail Tomaselli Brennan &amp; Baum LLP in Chicago and        Stephen Marshall of Venable LLP in Baltimore.     <\/p>\n<p>       <b>Status of Litigation<\/b>     <\/p>\n<p>       This is the fifth case regarding FOSAMAX<sup>\u00ae<\/sup> (alendronate        sodium) to go to trial. Merck won three of the first four. The first        three trials were conducted as part of the federal multidistrict        litigation proceedings before Judge Keenan. The first case to be tried        to a verdict, <i>Maley v. Merck<\/i>, resulted in a defense verdict for        Merck in May 2010. The second case to be tried to a verdict, <i>Boles v.        Merck<\/i>, initially resulted in a mistrial in September 2009 after the        jury was unable to reach a unanimous verdict. A retrial of that case in        June 2010 resulted in a plaintiff verdict, which was later reduced by        Judge Keenan and which Merck intends to appeal after the damages portion        of the case is retried. The third case to be tried to a verdict, <i>Graves        v. Merck<\/i>, resulted in a defense verdict for Merck in November 2010.        The fourth case to go to trial, <i>Rosenberg v. Merck<\/i>, which was        tried in the Superior Court for Atlantic County, New Jersey, resulted in        a defense verdict for Merck in February 2011.     <\/p>\n<p>       As of\u00a0June 30, 2011, approximately\u00a01,650 cases, which include        approximately\u00a02,050 plaintiff groups, had been filed and were pending        against Merck in either federal or state court.     <\/p>\n<p>       <b>About FOSAMAX<\/b>     <\/p>\n<p>       FOSAMAX is indicated for the treatment and prevention of osteoporosis in        postmenopausal women. The safety and effectiveness of FOSAMAX for the        treatment of osteoporosis are based on clinical data of four years        duration.\u00a0FOSAMAX should not be used in patients with certain disorders        of the esophagus that delay emptying, who are unable to stand or sit        upright for at least 30 minutes, who have low levels of calcium in their        blood, or in patients who are allergic to FOSAMAX. Some patients may        develop severe digestive reactions including irritation, inflammation or        ulceration of the esophagus. Patients who experience new or worsening        heartburn, difficulty or pain when swallowing or chest pain should stop        taking the drug and call their doctor right away. Patients who develop        severe bone, joint and\/or muscle pain at any time should contact their        doctor. Osteonecrosis of the jaw, generally associated with tooth        extraction and\/or local infection, with delayed healing, has been        reported in patients taking bisphosphonates, including FOSAMAX. Patients        who develop osteonecrosis of the jaw while on bisphosphonate therapy        should receive care by an oral surgeon. New or unusual hip, thigh or        groin pain should be evaluated, as atypical femoral (thigh bone)        fractures have been reported in patients taking bisphosphonates,        including FOSAMAX.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2F&amp;esheet=50015609&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=1&amp;md5=81ead9c5e3d44b744327ccd2ead424d5\">www.merck.com<\/a>        and connect with us on Twitter, Facebook and YouTube.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This statement includes \u201cforward-looking statements\u201d within the meaning        of the safe harbor provisions of the United States Private Securities        Litigation Reform Act of 1995. Such statements may include, but are not        limited to, statements about the benefits of the merger between Merck        and Schering-Plough, including future financial and operating results,        the combined company\u2019s plans, objectives, expectations and intentions        and other statements that are not historical facts. Such statements are        based upon the current beliefs and expectations of Merck\u2019s management        and are subject to significant risks and uncertainties. Actual results        may differ from those set forth in the forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the U.S. and internationally and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50015609&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=99781d70c2992faae57de2c3fb08725a\"><span class=\"bwuline\">www.sec.gov<\/span><\/a>).     <\/p>\n<p>       <b>The Prescribing information and Medication Guide for FOSAMAX<\/b><sup><b>\u00ae<\/b><\/sup><b>        are attached and are available at:<\/b>     <\/p>\n<p>       <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Ff%2Ffosamax%2Ffosamax_pi.pdf&amp;esheet=50015609&amp;lan=en-US&amp;anchor=www.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Ff%2FFOSAMAX%2FFOSAMAX_pi.pdf&amp;index=3&amp;md5=5bede243e0ea872513526a0618189363\"><b>www.merck.com\/product\/usa\/pi_circulars\/f\/FOSAMAX\/FOSAMAX_pi.pdf<\/b><\/a>     <\/p>\n<p>       <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Ff%2Ffosamax%2Ffosamax_mg.pdf&amp;esheet=50015609&amp;lan=en-US&amp;anchor=www.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Ff%2FFOSAMAX%2FFOSAMAX_mg.pdf&amp;index=4&amp;md5=19b28f2c79b69aa8ab8ce4a3ba01d8ef\"><b>www.merck.com\/product\/usa\/pi_circulars\/f\/FOSAMAX\/FOSAMAX_mg.pdf<\/b><\/a>     <\/p>\n<p>       <b>FOSAMAX<\/b><sup><b>\u00ae<\/b><\/sup><b> is a registered trademark of Merck        Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Whitehouse        Station, N.J., U.S.A.<\/b>     <\/p>\n<\/p>\n<p><p>       Merck<br \/>Media Contact:<br \/>Pam Eisele, 908-423-5042<br \/>or<br \/>Investor        Contact:<br \/>Carol Ferguson, 908-423-4465     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said a federal court jury in New York found in its favor in the Secrest v. Merck case, rejecting the claim of a Florida woman who blamed her dental and jaw-related problems on her FOSAMAX use. \u201cWe believe the company acted properly,\u201d said Chilton Varner of King &amp; Spalding LLP, outside counsel for Merck. \u201cUnfortunately, the plaintiff had medical problems that cause people to develop the jaw and dental problems that the plaintiff has, regardless of whether they were taking FOSAMAX. She has a long history of invasive dental procedures and suffers from medical conditions that inhibit the body\u2019s ability to heal.\u201d Today\u2019s verdict marks the fourth time a jury has found in Merck\u2019s favor on a plaintiff\u2019s product liability claim in the litigation regarding FOSAMAX. The plaintiff in this case alleged she used FOSAMAX and suffered various jaw problems and complications following multiple tooth extractions and failed<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742084","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX\u00ae (alendronate sodium) - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX\u00ae (alendronate sodium) - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said a federal court jury in New York found in its favor in the Secrest v. Merck case, rejecting the claim of a Florida woman who blamed her dental and jaw-related problems on her FOSAMAX use. \u201cWe believe the company acted properly,\u201d said Chilton Varner of King &amp; Spalding LLP, outside counsel for Merck. \u201cUnfortunately, the plaintiff had medical problems that cause people to develop the jaw and dental problems that the plaintiff has, regardless of whether they were taking FOSAMAX. She has a long history of invasive dental procedures and suffers from medical conditions that inhibit the body\u2019s ability to heal.\u201d Today\u2019s verdict marks the fourth time a jury has found in Merck\u2019s favor on a plaintiff\u2019s product liability claim in the litigation regarding FOSAMAX. The plaintiff in this case alleged she used FOSAMAX and suffered various jaw problems and complications following multiple tooth extractions and failed\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\\\/\",\"name\":\"Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX\u00ae (alendronate sodium) - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2011-10-03T10:54:00+00:00\",\"dateModified\":\"2026-08-10T17:01:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX\u00ae (alendronate sodium)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX\u00ae (alendronate sodium) - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\/","og_locale":"en_US","og_type":"article","og_title":"Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX\u00ae (alendronate sodium) - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said a federal court jury in New York found in its favor in the Secrest v. Merck case, rejecting the claim of a Florida woman who blamed her dental and jaw-related problems on her FOSAMAX use. \u201cWe believe the company acted properly,\u201d said Chilton Varner of King &amp; Spalding LLP, outside counsel for Merck. \u201cUnfortunately, the plaintiff had medical problems that cause people to develop the jaw and dental problems that the plaintiff has, regardless of whether they were taking FOSAMAX. She has a long history of invasive dental procedures and suffers from medical conditions that inhibit the body\u2019s ability to heal.\u201d Today\u2019s verdict marks the fourth time a jury has found in Merck\u2019s favor on a plaintiff\u2019s product liability claim in the litigation regarding FOSAMAX. The plaintiff in this case alleged she used FOSAMAX and suffered various jaw problems and complications following multiple tooth extractions and failed","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:16+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\/","name":"Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX\u00ae (alendronate sodium) - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2011-10-03T10:54:00+00:00","dateModified":"2026-08-10T17:01:16+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-federal-bellwether-trial-regarding-fosamax-alendronate-sodium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX\u00ae (alendronate sodium)"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"72267820-bd64-4b60-bbdb-c721babfec7e","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742084\/revisions"}],"predecessor-version":[{"id":3679220,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742084\/revisions\/3679220"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742084"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}